Ahmadi Hossein, Baharvand Hossein, Ashtiani Saeed Kazemi, Soleimani Massoud, Sadeghian Hakimeh, Ardekani Jalil Madjd, Mehrjerdi Narges Zare, Kouhkan Azam, Namiri Mehrnaz, Madani-Civi Manouchehr, Fattahi Fatemeh, Shahverdi Abdolhossein, Dizaji Ahmad Vosough
Tehran Heart Center, Tehran University of Medical Sciences, Tehran, I.R. Iran.
Curr Neurovasc Res. 2007 Aug;4(3):153-60. doi: 10.2174/156720207781387141.
The CD133(+) bone marrow cell (BMC) population includes primitive multipotent stem cells which induce neoangiogenesis. Studies suggested transplantation of these cells to infarcted myocardium can have a favorable impact on tissue perfusion and contractile performance. We assessed the feasibility, safety and functional outcomes of autologus CD133(+) BMC transplantation during coronary artery bypass grafting (CABG) in patients with recent myocardial infarction. In a prospective, nonrandomized, open-label study, 27 patients with recent myocardial infarction underwent CABG and intramyocardial injection of autologous bone marrow-derived CD133(+) cells (18 patients, BMC group) or CABG alone (9 patients, control group). At 6 months after CABG, the Wall Motion Score Index (WMSI) was significantly reduced for akinetic/dyskinetic segments treated with CD133(+) cells compared with the control group (P<0.006). Likewise, comparison between baseline and follow up results of dobutamine stress echocardiography and myocardial perfusion scintigraphy showed improvement of myocardial viability and local perfusion of the infarcted zone of the BMC group compared with the control group. No complications related to CD133(+) cell transplantation were noted, either procedurally or during postoperative at a mean of 14 months follow up. In patients with recent myocardial infarction, transplantation of CD133(+) cells to the peri-infarct zone during CABG surgery is feasible and safe, with no evidence of early or late adverse events. Moreover, these cells might restore tissue viability and improve perfusion of the infarcted myocardium, suggesting that they may induce myogenesis as well as angiogenesis.
CD133(+)骨髓细胞（BMC）群体包含可诱导新血管生成的原始多能干细胞。研究表明，将这些细胞移植到梗死心肌中可对组织灌注和收缩功能产生有利影响。我们评估了自体CD133(+) BMC移植在近期心肌梗死患者冠状动脉旁路移植术（CABG）期间的可行性、安全性和功能结局。在一项前瞻性、非随机、开放标签研究中，27例近期心肌梗死患者接受了CABG并心肌内注射自体骨髓来源的CD133(+)细胞（18例患者，BMC组）或仅接受CABG（9例患者，对照组）。CABG术后6个月，与对照组相比，接受CD133(+)细胞治疗的运动减弱/运动障碍节段的壁运动评分指数（WMSI）显著降低（P<0.006）。同样，多巴酚丁胺负荷超声心动图和心肌灌注闪烁显像的基线与随访结果比较显示，与对照组相比，BMC组梗死区的心肌活力和局部灌注有所改善。在平均14个月的随访期间，无论是在手术过程中还是术后，均未发现与CD133(+)细胞移植相关的并发症。对于近期心肌梗死患者，在CABG手术期间将CD133(+)细胞移植到梗死周边区域是可行且安全的，没有早期或晚期不良事件的证据。此外，这些细胞可能恢复组织活力并改善梗死心肌的灌注，表明它们可能诱导肌生成以及血管生成。
